XML 135 R118.htm IDEA: XBRL DOCUMENT v3.23.1
FINANCIAL INSTRUMENTS (Details 1)
¥ in Thousands, $ in Thousands
Dec. 31, 2022
USD ($)
Dec. 31, 2022
CNY (¥)
Dec. 31, 2021
CNY (¥)
Financial liabilities at amortized cost:      
Due to the Shareholder $ 1,037 ¥ 7,153 ¥ 14,050
Financial liabilities at amortised cost, class [member]      
Derivatives not designated as hedging instruments：      
Derivative financial liabilities (i) [1] 119 824 1,710
Financial liabilities at amortized cost:      
Trade payables 2,946 20,326 21,118
Financial liabilities in other payables and accruals 978 6,749 5,903
Dividends payable 5,048
Lease liabilities 422 2,915 2,189
Due to related companies 494 3,408 5,710
Due to the Shareholder | ¥   7,153 14,050
Due to the Shareholder | $ 1,037    
Interest-bearing loans and borrowings 10,729 74,000 77,000
Total 16,725 115,375 132,728
Total current 6,200 42,777 57,520
Total non-current $ 10,525 ¥ 72,598 ¥ 75,208
[1] On January 20, 2021, the Company entered into a securities purchase agreement with certain institutional investors, pursuant to which the Company issued and sold on January 22, 2021, (i) in a registered direct offering, an aggregate of 3,960,000 of its common shares at a price of US$1.85 per share, and (ii) in a concurrent private placement, warrants initially exercisable for the purchase of an aggregate of 1,584,000 of its common shares with an initial exercise price of US$2.35 per share.